Targeting Subviral Particles: A Critical Step in Achieving HBV Functional Cure but Where Are We with Current Agents in Clinical Development?

Affiliations

Editorial

Andrew Vaillant. Viruses. 2022.

. 2022 May 31;14(6):1193.

doi: 10.3390/v14061193.

Abstract

The recent review [...].

AV is an employee and shareholder of Replicor Inc.

HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.
Moini M, Fung S. Moini M, et al. Viruses. 2022 Mar 22;14(4):657. doi: 10.3390/v14040657. Viruses. 2022. PMID: 35458387 Free PMC article. Review.

1. Moini M., Fung S. HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure. Viruses. 2022;14:657. doi: 10.3390/v14040657. - DOI - PMC - PubMed
1. Vaillant A. Editorial: In vitro mechanistic evaluation of nucleic acid polymers: A cautionary tale. Mol. Ther. Nucleic Acids. 2022;28:168–174. doi: 10.1016/j.omtn.2022.03.002. - DOI - PMC - PubMed
1. Gane E., Yuen M.F., Yogaratnam J., Le K., Vuong J., Christopher W., Gohil V., Schwabe C., Agarwal K., Jucov A., et al. Safety, Tolerability and Pharmacokinetics (PK) of Single and Multiple Doses of ALG-010133, an S-antigen Transport Inhibiting Oligonucleotide Polymer (STOPS) for the Treatment of Chronic Hepatitis B. J. Hepatol. 2021;75:S741.
1. Aligos Aligos Halting Further Development of STOPS™ Drug Candidate, ALG-010133. Press Release. 2022. [(accessed on 8 May 2022)]. Available online: https://investor.aligos.com/news-releases/news-release-details/aligos-ha...
1. Vaillant A. REP 2139: Antiviral Mechanisms and Applications in Achieving Functional Control of HBV and HDV Infection. ACS Infect. Dis. 2019;5:675–687. doi: 10.1021/acsinfecdis.8b00156. - DOI - PubMed